Sign In
Buy DXCM
$72.77
-0.680 (-0.93%)
At Close: Jun 03, 2026
DexCom, Inc. (DXCM) Q3 2025 Earnings Call Transcript
08:26pm, Thursday, 30'th Oct 2025
DexCom, Inc. ( DXCM ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Sean Christensen - Vice President of Finance and Investor Relations Jacob Leach - Interim CEO, President &
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DexCom, Inc.
DexCom (DXCM) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
06:30pm, Thursday, 30'th Oct 2025
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Stre
DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
06:11pm, Thursday, 30'th Oct 2025
DexCom (DXCM) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.45 per share a year ago.
Dexcom beats quarterly estimates on strong demand for glucose monitors
04:03pm, Thursday, 30'th Oct 2025
Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.
Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
04:02pm, Thursday, 30'th Oct 2025
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance.
Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. and Certain Officers – DXCM
10:00am, Thursday, 30'th Oct 2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) and certain offic
Should You Buy DexCom Stock Before Oct. 31?
09:23am, Thursday, 30'th Oct 2025
Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations.
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
11:48pm, Wednesday, 29'th Oct 2025
LOS ANGELES--(BUSINESS WIRE)---- $DXCM--DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
The Complaint alleges DexCom made unauthorized G6 and G7 design changes, overstated reliability, and downplayed resulting health and regulatory risks.
Insights Into DexCom (DXCM) Q3: Wall Street Projections for Key Metrics
10:16am, Wednesday, 29'th Oct 2025
Beyond analysts' top-and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter e
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
09:46pm, Tuesday, 28'th Oct 2025
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DexCom, Inc.
DCXM ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc. Investors
04:57pm, Tuesday, 28'th Oct 2025
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired DexCom, Inc. (“DexCom” or the “Company”)
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of DexCom, Inc. (NASDAQ: D
